MedTrace Logo

"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"

NCT01121770 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2014-09-01

No results posted yet for this study

Summary

The purpose of this study is to determine a preventative dose of study drug, Arixtra® for patients with kidney disease. We will measure the blood levels of Arixtra® in patients with kidney disease and develop guidelines for dosing.

Conditions

  • Renal Insufficiency

Interventions

DRUG

fondaparinux sodium injection

1.5mg subcutaneously every day

Sponsors & Collaborators

Principal Investigators

  • Thomas L Ortel, M.D, PhD · Duke University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-10-31
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01121770 on ClinicalTrials.gov